For Prospective Patients

AuroLase® Therapy is investigational at this current time and only available through designated FDA sanctioned clinical study sites. Patients must be enrolled by the participating physician at that clinical study site, and must meet the enrollment criteria based on the physician's evaluation. 

Current Clinical Study - Recurrent or Refractory Head and Neck Cancer

Under FDA guidelines, we have received authorization for and began a human study in 2008 for the treatment of refractory or recurrent head and neck cancers with very specific patient criteria. Please note that "head and neck cancers" do not include tumors located in the brain; rather, these are soft tissue tumors of the oral cavity, nasal cavity and neck area.  The therapy is not available for other cancers or any hospitals other than the designated clinical study sites. 

Not all head and neck cancer patients will qualify for the study. A brief summary of the eligibility criteria are:

• Patients must have documented histological or cytological evidence of tumor(s) of the head and neck
• Patients must be > 18 years of age
• Patients must have ECOG Performance Score of 0, 1 or 2
• Patients or their legal representative must be able to read, understand and sign an informed consent
• Patients must meet minimum health requirements for renal and hepatic function
• Patient must not have had chemotherapy, radiation or other treatments within the 30 days prior to the AuroLase® Therapy procedure

Other Types of Cancer

Other cancer applications are under development. Updates regarding future clinical trials will be posted as they become available.

For Patients Previously Treated with AuroShell® Particles

For patients previously treated with AuroShell® particles , please contact your treating clinician with any questions. In the event of an emergency, please call 911 or proceed to the nearest emergency room.